Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

(2009) C. S. Tam et al.   BLOOD

Karyotype complements the International Prognostic Scoring System for primary myelofibrosis

(2009) Kebede Hussein et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD

Choosing between stem cell therapy and drugs in myelofibrosis

(2008) N Kröger et al.   LEUKEMIA

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

(2008) F Cervantes et al.   LEUKEMIA

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

(2008) A M Vannucchi et al.   LEUKEMIA